Your browser doesn't support javascript.
loading
Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).
Lau, Sai Ping; van 't Land, Freek R; van der Burg, Sjoerd H; Homs, Marjolein Y V; Lolkema, Martijn P; Aerts, Joachim G J V; van Eijck, Casper H J.
Afiliación
  • Lau SP; Department of Surgery, Erasmus MC, Rotterdam, The Netherlands.
  • van 't Land FR; Department of Surgery, Erasmus MC, Rotterdam, The Netherlands.
  • van der Burg SH; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Homs MYV; Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands.
  • Lolkema MP; Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands.
  • Aerts JGJV; Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • van Eijck CHJ; Department of Surgery, Erasmus MC, Rotterdam, The Netherlands c.vaneijck@erasmusmc.nl.
BMJ Open ; 12(6): e060431, 2022 06 16.
Article en En | MEDLINE | ID: mdl-35710239
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Vacunas contra el Cáncer Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: BMJ Open Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Vacunas contra el Cáncer Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: BMJ Open Año: 2022 Tipo del documento: Article